Systematic Reviews
Copyright ©The Author(s) 2023.
World J Gastroenterol. Oct 21, 2023; 29(39): 5503-5525
Published online Oct 21, 2023. doi: 10.3748/wjg.v29.i39.5503
Table 3 Summary area under the receiver operator curve and diagnostic odds ratio of noninvasive methods for prediction of significant fibrosis, advanced fibrosis and cirrhosis in autoimmune liver diseases patients
Disease
Diagnostic model/Stage
No. of studies (patients)
AUROC (95%CI)
DOR (95%CI)
AIHAPRI
SF4 (383)0.67 (0.63-0.71)3.87 (2.1-7.3)
AF10 (917)0.71 (0.67-0.75)3.85 (2.8-5.3)
Cirrhosis6 (543)0.71 (0.67-0.75)3.77 (2.2-6.4)
FIB-4
SF5 (459)0.74 (0.70-0.78)5.11 (3.1-8.5)
AF11 (962)0.73 (0.69-0.76)4.04 (2.4-6.8)
Cirrhosis6 (543)0.72 (0.68-0.76)5.48 (2.4-12.6)
TE
SF9 (523)0.84 (0.80-0.87)16.83 (8.8-32.2)
AF7 (460)0.88 (0.85-0.90)25.14 (9.7-65.3)
Cirrhosis7 (415)0.90 (0.87-0.92)91.77 (40.1-201.2)
AAR
AF6 (410)0.73 (0.69-0.77)4.94 (3.2-7.8)
2D-SWE
Cirrhosis4 (297)0.91 (0.89-0.94)30.68 (15.7-59.9)
PBCAPRI
SF4 (584)0.77 (0.73-0.80)6.27 (3.5-11.2)
AF15 (1589)0.70 (0.66-0.74)3.67 (2.3-5.9)
Cirrhosis6 (852)0.83 (0.79-0.86)14.55 (1.9-113.8)
FIB-4
AF13 (1296)0.79 (0.75-0.82)7.13 (4.0-12.8)
Cirrhosis6 (852)0.88 (0.85-0.91)29.79 (5.9-150.3)
TE
SF5 (446)0.93 (0.91-0.95)74.45 (12.2-455.5)
AF10 (880)0.93 (0.90-0.95)41.84 (19.3-91.0)
Cirrhosis6 (483)0.91 (0.88-0.93)134.83 (33.0-551.8)
AAR
AF6 (559)0.74 (0.70-0.78)4.13 (2.0-8.6)
Cirrhosis4 (407)0.88 (0.84-0.90)25.29 (9.0-70.9)
RPR
AF4 (362)0.53 (0.49-0.58)7.98 (4.0-15.8)
M2BP
AF4 (370)0.86 (0.82-0.88)13.17 (4.1-42.4)
PSCTE
Cirrhosis4 (207)0.95 (0.93-0.97)70.59 (15.4-322.7)